TARO-SITAGLIPTIN FUMARATE DIN 02531631
Status: Marketed
Holder: TARO PHARMACEUTICALS INC
Molecule: SITAGLIPTIN (SITAGLIPTIN FUMARATE)
Available to quote
Health Canada record
| Active ingredient(s) | SITAGLIPTIN (SITAGLIPTIN FUMARATE) 25 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | A10BH01 SITAGLIPTIN |
| Original market date | 05-Jan-2023 |
| Current status date | 05-Jan-2023 |
| Source | Health Canada DPD |
Establishment licence of the holder
Taro Pharmaceuticals Inc — licence 100232, not currently licensed, last inspection rating C (2025-03-24).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing SITAGLIPTIN (SITAGLIPTIN FUMARATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02531658 | TARO-SITAGLIPTIN FUMARATE | TARO PHARMACEUTICALS INC | Tablet | SITAGLIPTIN (SITAGLIPTIN FUMARATE) 50 MG | Marketed |
| 02531666 | TARO-SITAGLIPTIN FUMARATE | TARO PHARMACEUTICALS INC | Tablet | SITAGLIPTIN (SITAGLIPTIN FUMARATE) 100 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 29837 | 2023-01-05 | Abbreviated New Drug Submission (ANDS) |